Japanese Device Makers Unite To Develop Heart Pump In U.S.
This article was originally published in PharmAsia News
Japanese medical device makers Asahi Kasei and Misuzu & Sun Medical Holdings have entered into an agreement to develop and market Misuzu's implantable heart-assist device in the United States and elsewhere. Under the agreement, Asahi Kasei bought a 60 percent stake in Misuzu's U.S. subsidiary, Evaheart Medical USA for $7.5 million and is to cover the cost of clinical trials in the United States. The device under development is Misuzu's left ventricular assist system that helps the heart circulate blood via an implantable pump. The firm already has applied for approval in Japanese. (Click here for more - a subscription may be required)
You may also be interested in...
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.